The overexpression of the oncogene product MDM2 is often observed in human breast cancer cells, especially in estrogen receptor (ER)-positive ones. To study the role of MDM2 protein in ERpositive breast cancer, we have established cell lines derived from MCF-7 which stably express increased and decreased levels of MDM2 by transfection of a mammalian expression vector containing human mdm2 cDNA in sense and antisense orientations, respectively. Interestingly, MDM2 overexpression in MCF-7 cells afforded a remarkable growth advantage under estradiol (E 2 )-supplemented condition. Then, we analyzed the expression of p53, which is an important regulator of growth and the cell cycle. Unexpectedly, the p53 accumulation induced by E 2 was remarkably higher in MCF-7 cells stably overexpressing MDM2 than in the parent MCF-7 cells. On the other hand, reduction of MDM2 suppressed the E 2 -induced increase in p53 protein. Moreover, mdm2 antisense oligonucleotides prevented E 2 -induced accumulation of p53. In the steady state, the cellular levels of p53 were also correlated with those of MDM2. These interactions are not consistent with the well-known role of MDM2, which acts as a negative regulator for p53 by inhibiting its function and promoting its rapid degradation. These results suggest that MDM2 may regulate the expression of p53 in the steady state and in response to E 2 in breast cancer cells, and imply a novel and important role of MDM2 during breast carcinogenesis.
The mdm2 oncogene was originally identified as a highly amplified gene on a murine double-minute chromosome in the 3T3DM cell line, a spontaneously transformed derivative of BALB/c3T3 cells. 1, 2) The corresponding human mdm2 gene was also identified.
3) Overexpression of the mdm2 gene in NIH3T3 cells increases its tumorigenic potential, thus establishing mdm2 as an oncogene.
2) The gene encodes a polypeptide consisting of 489 amino acids that contains a binding domain for the tumor suppressor p53, an acidic region, zinc finger motifs and a ring finger domain. 2, [4] [5] [6] MDM2 is believed to bind to the N-terminal region of p53 and to inhibit its transcriptional activity by masking its transactivation domain. 3, 4) Recently, it was also shown that MDM2 promoted the rapid degradation of p53. 7, 8) In contrast, p53 induces the expression of MDM2 via binding to its promoter region, suggesting that MDM2 can function as a negative feedback regulator of p53. 4, 9) In addition to regulating p53, MDM2 has also been shown to interact with many other molecules, such as the retinoblastoma protein pRB, 10) E2F transcriptional factor, 11) ribosomal protein L5, 12) RNA, 13) cell fate regulator Numb, 14) and cell cycle inhibitor p19
Arf . 15, 16) Interaction with pRB and with E2F1/DP1 promoted G1/S cell cycle progression through disrupting RB function and stimulating transcriptional activity of E2F1. 10, 11) Binding to the ribosomal protein L5 suggests the possibility that MDM2 may enhance the translation process. The association with Numb may influence processes such as differentiation and survival following reduction in overall cellular Numb levels. Based on the above results, together with the observation showing the existence of alternatively spliced forms of MDM2 that cannot bind p53 in various types of cancer cells, 17, 18) there is a possibility that MDM2 may play an important role in cell growth and differentiation in a p53-independent fashion.
The mdm2 gene is amplified or overexpressed in 40-60% of human osteogenic sarcomas and about 30% of soft tissue sarcomas. 3, 19) Although mdm2 gene amplification is uncommon in breast cancers, as in other epithelial tumors, 20, 21) the level of its mRNA and/or protein is upregulated in about 40% of breast cancer specimens. [22] [23] [24] [25] Interestingly, there was a significant positive correlation between the levels of MDM2 and estrogen receptor (ER) in breast cancer specimen and breast cancer cell lines.
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In contrast to ER-negative cell lines, all ER-positive cells express elevated levels of mdm2 mRNA. 26) In order to gain further insight into the role of MDM2 in ER-positive breast cancer cells, we have established cell clones derived from MCF-7 which stably express increased and decreased levels of MDM2. To our surprise, both steady-state expression and estradiol (E 2 )-induced accumulation of p53 were positively correlated to the levels of MDM2 protein, which has previously been believed to promote the rapid degradation of p53.
MATERIALS AND METHODS
Cells and cell culture A breast cancer cell line MCF-7 was obtained from the National Cancer Institute (Bethesda, MD). MCF-7 cells were maintained routinely in Dulbecco's modified Eagle's medium (DMEM, Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Gibco BRL), 1 nM 17β-estradiol (E 2 , Wako Pure Chemical Industries, Osaka), 100 units/ml penicillin G and 100 µg/ml streptomycin. For experiments evaluating the effect of E 2 , cells were cultured in phenol red-free DMEM (PRF-DMEM, Gibco BRL) containing 10% FBS stripped of steroids by absorption with dextrancoated charcoal (DCC-FBS).
Establishment of MDM2-expressing transfectant
Transfection into MCF-7 cells of mammalian expression vectors containing human mdm2 cDNA, pCmdm2 and pCmdm2as, which were supplied by Dr. Klaus Roemer (University of California, San Diego), 27) was performed as described previously. 28) Briefly, cells transfected using lipofectin (Gibco BRL) were selected in the culture medium containing 600-800 µg/ml G418 (Gibco BRL). G418-resistant colonies were cloned after 2-3 weeks and maintained in the culture medium containing 200 µg/ml G418. The clones showing changes of MDM2 expression as compared to the parent MCF-7 cells were screened by western blotting. Colony formation assay in soft agar Three thousand cells were suspended in 300 µl of 0.3% Difco's noble agar in 10% DCC-FBS/PRF-DMEM and layered over 300 µl of 0.6% agar-medium basal layer in 24-well tissue culture plates. Cells were then fed with 10% DCC-FBS/PRF-DMEM supplemented with or without 1 nM E 2 and incubated at 37°C for 16 days. Culture medium was replaced every 3 days. On day 16, the number of colonies >30 µm in diameter was counted under a microscope. Western blotting Cells were washed twice with ice-cold phosphate-buffered saline (PBS) and harvested in lysis buffer (1% Triton X-100, 50 mM NaCl, 25 mM Hepes (pH 7.4), 2 mM EDTA, 1 mM PMSF, 10 µg/ml leupeptin). Cell lysates were scraped into microcentrifugation tubes and centrifuged for 10 min at 12,000g. The resulting supernatants were transferred to fresh tubes. Protein contents were determined by using a Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA). Proteins were separated by 7.5%, 9% or 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently electrophoretically transferred onto polyvinylidene difluoride (PVDF) membranes (Millipore, Bedford, MA). To assess the quality of electrophoretic transfer, prestained SDS-PAGE standards (Bio-Rad) were used. The membrane was incubated for 24 h in blocking buffer (2% skimmed milk, 0.1% Tween-20 in 20 mM Tris-buffered saline pH 7.5; TBS-T) at 4°C. After having been washed with TBS-T, the membrane was incubated with the respective antibody for 1 h. MDM2 was detected using 1 µg/ml Ab-1 (IF2) mouse monoclonal antibody (Oncogene Research Products, Cambridge, MA), p53 was detected using 0.1 µg/ml Ab-6 (DO-1) mouse monoclonal antibody (Oncogene Research Products), p21 was detected using 1 µg/ml C-19 rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and actin was detected using 2 µg/ml Ab-1 mouse monoclonal antibody (Oncogene Research Products). Membranes were washed with TBS-T and incubated with horseradish peroxidaseconjugated anti-mouse IgG, anti-rabbit IgG (Amersham, Buckinghamshire, UK) or anti-mouse IgM (Oncogene Research Products), then probed by the ECL chemiluminescence technique (Amersham) according to the manufacturer's recommendations. Band density was quantified by using a densitometer (Atto Densitograph, Tokyo). UV irradiation Cells (2×10 5 ) were seeded in 35-mm tissue culture dishes and incubated for more than 24 h at 37°C under 5% CO 2 . The medium was removed and the cells were irradiated with a 15-W germicidal lamp delivering 0.04 mW/cm 2 /s of UVc at a distance of 30 cm. The irradiation was continued for 5 s and resulted in 0.2 mJ/ cm 2 UV exposure, which was quantitated with a UVR-305 UV-radiation meter (Topcon, Tokyo). After incubation for indicated periods of time with 10% DCC-FBS/ PRF-DMEM in the absence of E 2 , cell lysates were prepared for western blotting.
Antisense phosphorothioate oligonucleotide treatment
The antisense oligonucleotides for mdm2 were designed according to the report of Chen et al. 29) In order to evaluate sequence-specific effects, mismatch oligonucleotide, which contained the same amount of each nucleotide with a different sequence, was used as a control. The 20-mer antisense or mismatch phosphorothioate oligonucleotide was synthesized and purified by preparative reverse-phase HPLC. Cells (2×10 5 ) were cultured in 10% DCC-FBS/ PRF-DMEM without E 2 for over 24 h in 35-mm tissue culture dishes. Before oligonucleotide treatment, 5 µl of lipofectamine (Gibco BRL) was incubated with 200 µl of Opti-MEM I (Gibco BRL) and various concentrations of oligonucleotide at room temperature for 40 min. The cells were washed twice with Opti-MEM I, then oligonucle-otide-lipofectamine complexes were added to the culture dishes containing 800 µl of Opti-MEM I. After incubation of the dishes for 6 h, 1 ml of 20% DCC-FBS/PRF-DMEM was added and incubation was continued for another 18 h with or without 10 nM E 2 . Statistical analysis The statistical significance of differences in the results was evaluated by means of one-factor analysis of variance (ANOVA), and P values were calculated by the Bonferroni method. In the assay using AS oligo, Student's t test was used for evaluating the efficiency of inhibition.
RESULTS

Establishment of MCF-7 cells expressing increased or decreased level of MDM2
To study whether overexpression of MDM2 affects biological responses in breast cancer cells, we have established two types of cell clones derived from MCF-7 cells by transfecting plasmids, pCmdm2 expressing human mdm2 and pCmdm2as containing mdm2 cDNA in the antisense orientation. As shown in Fig. 1 , the 90 kDa form of MDM2 protein was predominant and an additional protein with a molecular weight of about 60 kDa was also detected in all cell clones. MCF-7/pCmdm2, clone s1 and clone s3 expressed 3.8-fold and 3.0-fold more MDM2 protein than the parent MCF-7, respectively. In contrast, MCF-7/pCmdm2as, clone as4 and clone as5 expressed less than half as much MDM2 protein compared with MCF-7.
Overexpression of MDM2 in MCF-7 cells afforded E 2 -dependent growth advantage
First, we examined whether the stable expression of MDM2 in MCF-7 cells alters their proliferative ability. The soft agar colony formation assay was designed to evaluate proliferative ability under anchorage-independent conditions. In the absence of E 2 , 10.0±2.0, 5.3±3.2, 7.3±3.1, 24.6±2.5 and 19.3±2.5 colonies/one well of 24-well tissue culture plate were observed in MCF-7, MCF-7/pCmdm2 (clone s1), MCF-7/ pCmdm2 (clone s3), MCF-7/pCmdm2as (clone as4) and MCF-7/pCmdm2as (clone as5), respectively (mean±SD, n=6) (Fig. 2) . Addition of 1 nM E 2 increased the number of colonies to 25.0±4.5, 90.0±22.6, 87.3±15.5, 58.3±17.6 and 54.0±9.6 in MCF-7, clone s1, clone s3, clone as4 and clone as5, respectively. Unexpectedly, the number of colonies was increased in MCF-7/pCmdm2as clones both in the absence and presence of E 2 compared with the parent MCF-7. However, their growth acceleration in response to E 2 was almost equivalent to that of MCF-7 (2.5-fold). A significantly high growth ratio (10-fold) in response to E 2 was observed in MCF-7/pCmdm2 clones (P<0.01 compared with MCF-7 and MCF-7/pCmdm2as clones). These data indicate that overexpression of MDM2 results in a prominent growth advantage under E 2 -supplemented conditions. Fig. 1 . MDM2 protein expression in parent MCF-7 and four types of cell clones transfected with pCMV containing human mdm2 cDNA in sense (MCF-7/pCmdm2) or antisense orientation (MCF-7/pCmdm2as). After incubation for 24 h in phenol red-free DMEM containing 10% FBS stripped of steroids, cells were harvested in Laemmli's sample buffer. Proteins were separated by SDS polyacrylamide gel (9%) electrophoresis and transferred onto PVDF membrane. The membranes were probed with the anti-MDM2 antibody (Ab-1). After stripping off the anti-MDM2 antibody, actin was probed as an internal control with monoclonal antibody (Ab-1). Fig. 2 . Overexpression of MDM2 in MCF-7 affords a growth advantage under E 2 -supplemented conditions. Three thousand cells were suspended in 0.3% Difco's noble agar containing 10% DCC-FBS/PRF-DMEM and layered over 0.6% agar medium in a 24-well tissue culture plate. Culture medium with or without 1 nM E 2 overlaid on the top layer was replaced every 3 days. On day 16, the numbers of colonies over 30 µm in diameter were counted. The results shown are means±SD from two separate experiments, each performed in triplicate. E 2 −, E 2 +. E 2 increased p53 expression, especially in MCF-7 cells overexpressing MDM2 The tumor suppressor p53 is a crucial regulator of cell growth through transactivation of p53-responsive genes such as p21/waf-1, an inhibitor of cyclin-dependent kinase. [30] [31] [32] Recent evidence has suggested that E 2 treatment of MCF-7 induces the accumulation of p53. 33, 34) Moreover, it was also shown that p53 may function as a negative regulator of the ER signaling pathway. 35) The above results suggest the possibility that overexpression of MDM2 induced the rapid degradation of p53 in MCF-7/pCmdm2, resulting in progression of ER-mediated transcription and a decrease of cell cycle inhibitor. Therefore, the levels of p53 protein in these cells were analyzed. Among four established clones, the results obtained from clone s1 (MCF-7/pCmdm2) and clone as4 (MCF-7/pCmdm2as) are shown in the following figures, since the data obtained from clone s3 and clone as5 were almost identical to those from clone s1 and clone as4, respectively. Fig. 3 shows p53 expression at 24 h after addition of various concentrations of E 2 , as assessed by western blotting of cell lysates. Prior to addition of E 2 , cells were maintained for 48 h in phenol redfree DMEM containing 10% FBS stripped of steroids. It should be noted that the level of p53 was higher in MCF-7/pCmdm2 than in the parent MCF-7 in the absence of E 2 (indicated as 0 nM E 2 in Fig. 3 ). Also in MCF-7/pCmdm2as, p53 expression paralleled the level of MDM2; both were lower than those in the parent MCF-7. In MCF-7, p53 accumulation was observed at 0.1 nM E 2 and its expression increased in a concentration-dependent manner. MCF-7/pCmdm2 showed a remarkable elevation of p53 protein even at 0.1 nM E 2 (P<0.05, compared with MCF-7). In contrast, only a modest increase in p53 was observed in MCF-7/pCmdm2as.
When the cells were treated with 10 nM E 2 for 3-48 h, an increase in the p53 protein was detectable at 6 h, and its elevation was maintained for up to 48 h (Fig. 4A) . p53 protein was expressed to a greater extent in MCF-7/ pCmdm2 than in the parent MCF-7 (P<0.01). On the other hand, MCF-7/pCmdm2as expressing the reduced level of MDM2 showed a lower expression of p53 than MCF-7 (P<0.01). Under the same conditions, MDM2 protein in MCF-7 cells increased gradually and almost doubled at 48 h (Fig. 4B) . In MCF-7/pCmdm2, MDM2 increased rapidly within 6 h and maintained its elevated level for at least 48 h (P<0.01, compared with MCF-7). In contrast, the induction of MDM2 was inhibited in MCF-7/ pCmdm2as (P<0.01, compared with MCF-7).
These unexpected results imply that not only in the steady state, but also in response to E 2 , the expression level of p53 correlates with that of MDM2, despite the well-known role of MDM as a promoter of p53 degradation 7, 8) and the results of growth assay. Therefore, in addition to protein level, the transcriptional activity of p53 in response to E 2 was assessed by measuring the protein level of p21/waf-1, expression of which is dominantly controlled by the transcriptional function of p53. [30] [31] [32] In MCF-7 and MCF-7/pCmdm2as, p21 time-dependently increased and was almost doubled at 48 h (Fig. 4C) . However, E 2 -induced p21 expression was most prominent in MCF-7/pCmdm2 (P<0.01, compared with MCF-7). The increase was detectable as early as 6 h after E 2 treatment and reached more than 3-fold at 48 h. UV-induced p53 expression was repressed in MCF-7 overexpressing MDM2 Since MCF-7/pCmdm2 expressed full-length MDM2 derived from exogenously introduced cDNA, we must confirm the ability of this MDM2 to promote the degradation of p53 under other conditions. Fur- Fig. 3 . Concentration-dependent effect of E 2 on p53 expression. Cells were maintained in medium without E 2 for 48 h and then incubated with various concentrations of E 2 for another 24 h. (A) Typical western blots. Cellular proteins were separated by 7.5% SDS-PAGE and transferred onto PVDF membranes. The membranes were probed with p53 monoclonal antibody (Ab-6). (B) Band density was quantified with a densitometer. The data (means±SD; n=3) shown are expressed as the increase (fold) over the value obtained in parent MCF-7 in the absence of E 2 (control).
MCF-7/pCmdm2, MCF-7, MCF-7/ pCmdm2as. * P<0.05, * * P<0.01 compared with MCF-7. thermore, to establish whether the cooperative increase in MDM2 and p53 was restricted to E 2 stimulation, the changes of p53 expression were examined in response to UV exposure, which is one of the most effective inducers of p53. [36] [37] [38] Treatment of cells with UV resulted in a timedependent increase in the level of p53 (Fig. 5) . In MCF-7/ pCmdm2, p53 induction was inhibited by overexpressed MDM2 after 24 h. In contrast, MCF-7/pCmdm2as showed the most prominent p53 induction, probably due to its reduced MDM2 expression. E 2 -induced p53 up-regulation was suppressed by transient reduction of MDM2 by antisense oligonucleotide The results obtained raised the possibility that the accumulation of p53 induced by E 2 was enhanced by MDM2 protein. To address this question, the production of MDM2 protein was transiently prevented by antisense oligonucleotide (AS oligo). 29) Treatment of MCF-7 cells with AS oligo resulted in a dose-dependent decrease in the level of MDM2 (Fig. 6B) . The level of MDM2 was slightly up-regulated by E 2 as compared with its absence. Fig. 6C showed the changes of p53 expression in response to various concentrations of MDM2 AS oligo. In the absence of E 2 , p53 expression was proportional to the increase of AS oligo concentration. In sharp contrast, in the presence of 10 nM E 2 , the level of p53 was reduced by MDM2 AS oligo, probably due to the inhibition of MDM2 expression. These results clearly indicate that E 2 -induced accumulation of p53 correlated well with the level of MDM2 protein.
DISCUSSION
The results obtained in the present study imply a possible novel role of MDM2 in MCF-7 cells. MDM2 overexpression in MCF-7 cells afforded a growth advantage under E 2 -supplemented conditions. In these cells, however, p53 accumulation induced by E 2 was remarkably higher than that in the parent MCF-7 cells. On the other Fig. 4 . Time-dependent effects of E 2 on p53, MDM2 and p21 expression. After preincubation for 48 h in medium without E 2 , cells were stimulated with 10 nM E 2 for the indicated periods of time. p53 (A), MDM2 (B) and p21 (C) proteins were assessed by western blotting with p53 monoclonal antibody (Ab-6), MDM2 monoclonal antibody (Ab-1) and p21 polyclonal antibody (C-19), respectively. Upper panels are typical western blots from three separate experiments. Band density was quantified with a densitometer and data (means±SD; n=3) are expressed as increase (fold) over the value obtained in parent MCF-7 at 0 time (control).
MCF-7/pCmdm2, MCF-7, MCF-7/pCmdm2as. * P<0.05, * * P<0.01 compared with MCF-7. MCF-7/pCmdm2, MCF-7, MCF-7/pCmdm2as. hand, reduction of MDM2 suppressed E 2 -induced p53 accumulation. Also, changes of steady-state MDM2 expression caused a proportional increase or decrease in the level of p53, indicating that they might maintain a balance.
MDM2 is well known to act as a negative regulator of p53 by inhibiting its ability to activate transcription and by promoting its rapid degradation.
3, 4, 7) Kubbutat et al. reported that transient overexpression of MDM2 inhibited the accumulation of both endogenous and exogenous p53 in a dose-dependent manner. 8) However, there are several observations which are consistent with our findings showing a paradoxical relationship between MDM2 and p53. Many investigators reported high expression of both MDM2 and wild-type p53 in soft tissue sarcomas, 19) bladder carcinomas, 39) testicular germ cell tumors, 40) nonHodgkin's lymphomas, 41) melanomas 42) and breast cancers. 42) Moreover, extended half-lives of wild-type p53 have been found in some choriocarcinoma cell lines which contain elevated levels of MDM2. 43) These observations could be explained by the possibility that the elevated p53 induced MDM2 overproduction. However, Keleti et al. reported that in a subset of rhabdomyosarcoma cell line with MDM2 gene amplification, the wildtype p53 protein is also elevated and both p53 and MDM2 were co-localized in the same nuclei. 44) In addition, both mutant-type p53 and MDM2 were elevated in some tumors. 19, 45, 46) These intricate interactions between MDM2 and p53 in the steady-state could not be explained by the mechanism previously reported. Therefore, it is reasonable to speculate that other mechanisms may regulate the expression levels of MDM2 and p53 via enhancement of transcription and/or protein stability.
In our preliminary investigations demonstrating E 2 -induced accumulation of p53 and MDM2, we confirmed that MDM2 accumulation was dependent on enhanced transcription from the mdm2-P2 promoter, which possesses two p53 binding motifs. 42, 47) In other words, the MDM2 level was under the control of p53 (data not shown). In the reverse transcriptase-polymerase chain reaction assay using promoter-specific primers, the mdm2-P2 transcript in MCF-7 was transiently observed at 6 h after addition of E 2 . In contrast, it was maintained from 6 to 24 h in MCF-7/pCmdm2. It is tempting to speculate that accumulated MDM2, which was up-regulated by p53, may in turn enhance the p53 expression via direct or indirect transcriptional activation. This is compatible with the findings that MDM2 possesses zinc finger motifs of the type found in DNA-binding proteins and an acidic domain that has transcriptional activity. 6, 48, 49) Alternatively, E 2 may enhance the protein stability of MDM2 and p53. These possibilities are under investigation in our laboratory.
MDM2 is frequently overexpressed in human breast cancer cells, [22] [23] [24] [25] and ER-positive breast cancer cell lines express relatively high levels of mdm2 mRNA and protein compared to ER-negative cells. 26) These findings strongly suggest the biological significance of MDM2 in ER-positive breast cancer. In fact, overexpression of MDM2 in MCF-7 cells affords a growth advantage under E 2 -supplemented conditions, although the mechanism of this growth acceleration has not yet been established. The prominent accumulation of the cell cycle inhibitor p21/ waf-1 and its inducer p53 in MCF-7/pCmdm2 seems incompatible with the results obtained in growth assay. Further experiments are necessary to understand whether the intricate interactions between MDM2 and p53 in response to E 2 were specific in breast cancer cells and to gain further insight into the mechanism regulating this novel interaction.
In summary, our findings presented here indicate a novel function of MDM2 in regulating p53 expression in breast cancer. This may provide a clue for better understanding the relationship between the tumor suppressor and the oncogene product, and suggest a possible novel function of MDM2, which may promote cell growth in breast cancer cells independently of p53 inhibition.
